GlaxoSmithKline Partners with Singapore for Formulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GlaxoSmithKline Partners with Singapore for Formulation


GlaxoSmithKline (GSK) and the Institute of Chemical and Engineering Sciences (ICES) of Singapore’s Agency for Science, Technology and Research’s have signed a five-year strategic agreement to develop new evidence-based formulations (EBFs) specifically for emerging markets. .EBFs are often fixed-dose combinations of active drugs or new formulations with different pharmacokinetic properties, new routes of delivery, or improved safety profiles. ICES has a long standing relationship with GSK since 2003, and the development of EBFs will further strengthen the relationship between both parties. The collaboration leverages ICES’ strengths and expertise in synthesis, formulation and process development and GSK’s vast experience in drug-candidate selection, optimization, and product development in novel formulations. The collaboration will enhance ICES’ technical expertise and know-how in drug product formulation, analytical techniques, development and scale-up. It will develop a pool of local expertise in specialized formulation for pharmaceutical development in Singapore.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
28%
Attracting a skilled workforce
28%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here